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ABSTRACT 
Hemodynamic functional ultrasound imaging (fUS) of neural activity provides a unique combination of spatial coverage, 
spatiotemporal resolution and compatibility with freely moving animals. However, deep and transcranial monitoring of brain 
activity and the imaging of dynamics in slow-flowing blood vessels remains challenging. To enhance fUS capabilities, we 
introduce biomolecular hemodynamic enhancers based on gas vesicles (GVs), genetically encodable ultrasound contrast agents 
derived from buoyant photosynthetic microorganisms. We show that intravenously infused GVs enhance ultrafast Doppler 
ultrasound contrast and visually-evoked hemodynamic contrast in transcranial fUS of the mouse brain. This hemodynamic 
contrast enhancement is smoother than that provided by conventional microbubbles, allowing GVs to more reliably amplify 
neuroimaging signals.
INTRODUCTION 
Functional ultrasound imaging (fUS) is a breakthrough 
technology that uses ultrafast frame rates to map changes in 
local cerebral blood volume induced by neural activity (1). Due 
to its high spatiotemporal resolution and versatile form factor, 
fUS has emerged as an attractive basic neuroscience tool 
capable of visualizing whole-brain functional activity in a 
variety of animal models and humans (2), providing functional 
resolution of the order of 100 μm (3, 4). 
Unfortunately, skull bones attenuate and distort 
ultrasound waves in the MHz range (5), which hinders the fully 
noninvasive potential of fUS imaging. As a result, except for a 
few studies (6), the vast majority of fUS imaging has been 
conducted using craniotomies (1, 4, 7, 8), thinned-skull 
preparations (9), or acoustically transparent windows (2, 10). 
A potential solution to compensate for skull attenuation is 
to augment the source of contrast in fUS – red blood cells – by 
administering ultrasound contrast agents into the blood 
stream. Errico et al. (9) showed that commercial lipid-shelled 
microbubbles (MBs) can enhance transcranial hemodynamic 
signals in rats. However, despite clear improvements in signal, 
this approach suffered from several limitations related to the 
physics of MBs. First, as MB-backscattered intensity decays 
rapidly over time due to gas diffusion (11), organ retention (12) 
and MB deflation upon ultrasound exposure (13), it was 
necessary to administer 13 bolus injections of MBs in rats over 
the course of 10 minutes (9), resulting in an exceptionally high 
dose. A second limitation is that MBs add significant random 
fluctuations to fUS signals (see (9), and Fig. 3F), which lowers 
the correlation score of functional activity maps. These 
fluctuations are likely due to the variability in the acoustic 
response of MBs of a given size (14), the lipid shell surface 
tension (15), the agent polydispersity (diameters ranging from 
~ 1 μm to >10 μm), and the pressure-dependent attenuation 
and scattering of MBs (16). 
Here, we introduce a new class of hemodynamic 
enhancers for fUS based on acoustic biomolecules known as 
gas vesicles (GVs) (17, 18). GVs comprise air-filled 
compartments with dimensions on the order of 200 nm, 
enclosed by a 2 nm-thick protein shell. These nanostructures 
were recently introduced as biomolecular ultrasound contrast 
agents and acoustic reporter genes (19-22). We hypothesized 
that the physical properties of GVs would provide potential 
advantages for hemodynamic enhancement. GVs are 
physically stable, relatively monodisperse in their cylindrical 
diameter, and much smaller than MBs. Thus, at comparable 
gas volume fractions these more numerous, stable, and 
monodisperse contrast agents are expected to boost 
hemodynamic contrast with substantially less fluctuation. Here 
we tested this hypothesis by examining the fUS enhancement 
provided by GVs purified from Anabaena flos-aquae (23), which 
in their wild-type form serve as non-resonant linear scatters at 
biomedical ultrasound frequencies (1-30 MHz) (24). We 
compared these biomolecular contrast agents to commercial 
MBs in vitro and in vivo. 
MATERIAL AND METHODS 
Gas vesicle preparation 
Gas vesicles were isolated from Anabaena flos-aquae via 
hypertonic lysis and buoyancy purification using previously 
described protocols (23). Their concentration was measured 
using their optical density at 500 nm (OD500nm). 
Flow phantom design 
To estimate the flow detection limit of GV-enhanced fUS 
imaging, we prepared three model solutions containing 
subwavelength ultrasound scatterers (Fig. 1A). The first 
solution was a commercial Doppler fluid (DF) (Model 707, 
ATS Laboratories, Bridgeport CT, USA) containing linear 
particles mimicking red blood cell scattering. The second 
solution contained the DF mixed with a commercial MB 
contrast agent (SonoVue, Bracco Imaging, Geneva, 
Switzerland) diluted at a ratio of 1:1000 (5 x 105 microbubbles 
per mL). The third solution contained the DF mixed with 
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purified gas vesicles (23) at a concentration of 1011 GVs per 
mL. Each solution was flowed through a 1.5 mm diameter 
channel extruded in a tissue-mimicking ultrasound phantom 
(1% cellulose embedded in 5% agar solution) using a syringe 
pump (GenieTouch, Kent Scientific Corportion). The channel 
and the surface of the phantom both formed a 5° angle with 
respect to the ultrasound probe (Fig. 1B) in order to prevent 
attenuation heterogeneity due to different phantom thickness 
above the channel. 
Functional ultrasound imaging sequence 
Ultrasound imaging was performed at 15 MHz using a 128-
element linear probe (Vermon, Tours, France) connected to a 
programmable ultrasound scanner (Verasonics Vantage, 
Seattle, USA). We transmitted angled ultrasound plane-waves 
(-6:2:6 degrees) at a 7 kHz framerate, which resulted in a 1 kHz 
framerate after coherent compounding (25). Ensembles of 200 
compounded frames were acquired every 0.5 s and processed 
using a singular value decomposition (SVD) filter (26) to 
generate power Doppler images (27) of the flow phantom (Fig. 
1C) or of the mouse brain (Fig. 2B), resulting in a 2 Hz fUS 
imaging framerate. 
In the flow phantom study, we selected an ultrasound 
imaging plane displaying the longitudinal cross section of the 
phantom channel (Fig. 1C), which was positioned at the 
geometric focus of the ultrasound probe (8 mm). For in vivo 
experiments, we selected manually the plane of interest that 
contained the lateral geniculate nuclei (LGN) – a sub-cortical 
structure of the mouse visual system (Fig. 2A) – and positioned 
the outer skull surface at a 2.5 mm distance from the 
ultrasound probe surface. 
Flow phantom data processing 
To quantify fUS signal enhancement for each of the contrast 
agent solutions injected in the phantom channel, we manually 
selected a region-of-interest inside the channel (ROI) as 
illustrated in Fig. 1C. Each data point shows the mean±SEM 
resulting from 30 measurements. First, we investigated the 
resistance of the different solutions to ultrasound pressure in 
these flow phantom conditions. Each solution was injected at 2 
mm/s and insonated with peak positive pressures ranging from 
135 kPa to 2.1 MPa. We calculated the contrast-to-Doppler-
fluid ratio (CFR) in decibels (dB) by measuring the mean power 
Doppler intensities (𝑃𝑊𝐷$$$$$$$) in the ROI for the ultrasound 
contrast agent (UCA) and the Doppler fluid (DF) respectively, 
according to the following formula: 𝐶𝐹𝑅()*) = 10 log23 4𝑃𝑊𝐷$$$$$$$567𝑃𝑊𝐷$$$$$$$89 : 
Then, using the syringe pump, each scattering solution was 
circulated in the phantom channel at flow velocities ranging 
from 5 mm/s to 20 μm/s and insonated at 254 kPa and 592 
kPa. The corresponding Doppler-derived flow velocities were 
extracted by retrieving the Doppler frequency fDoppler from the 
phase of the signal, and from the knowledge of the channel 
angle θ relative to the ultrasound propagation direction, 
according to the following classic formula: 𝑣<=>??@A@A = 	 𝑐3𝑓8EFFG@A2𝑓5I cos 𝜃 
 
Figure 1. GVs estimate slow flows more accurately and sustain higher pressure than MBs. A/ The three contrast enhancing 
solutions investigated: Doppler fluid (DF), microbubbles (MBs) and gas vesicles (GVs). B/ Schematic of the flow phantom setup. C/ 
Conventional ultrasound B-mode image indicating the selected ROI, and corresponding power Doppler image of the flow phantom. D/ 
Contrast-to-Doppler-fluid ratio (CFR) as a function of pressure at a flow velocity of 2 mm/s. E/ Flow measurement correspondence of DF, 
GV, and MB-enhanced ultrafast Doppler imaging at 254 kPa. F/ Flow measurement correspondence of DF, GV, and MB-enhanced ultrafast 
Doppler imaging at 592 kPa. 
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where c0 is the speed of sound in the medium of interest, and 
fUS is the transmitted ultrasound frequency.  
Animal preparation 
All in vivo experiments were approved by the Institutional 
Animal Care and Use Committee of the California Institute of 
Technology. C57BL/6J male mice aged between 9 and 11 
weeks were used in this study. Mice were anaesthetized using 
1–2.5% isoflurane using a nose cone, depilated over the head 
and placed on a 37 °C heating pad. A catheter was inserted in 
the tail vein for injection and affixed in place using GLUture. 
Mice were then anesthetized with Ketamine/Xylazine and 
placed on a stereotaxic frame for the imaging session. 
Ultrasound gel, previously centrifuged at 2000 G for 10 
minutes to remove bubbles, was applied to couple the 
transducer probe to the animal. 45 s after the beginning of the 
imaging sequence, 50 µL of saline, GVs (OD500nm=100, 
corresponding to 11.4 nM) or Definity MBs (Lantheus Medical 
Imaging, N. Billerica, MA, USA) diluted to 108 
microbubbles/mL were injected intravenously using the 
catheter. The rate of injection was 5 µL/s.  
The catheter was made from PE10 tubing and a 30 G 
needle. MBs were handled according to the manufacturer’s 
instructions and passed through a 30G needle only during 
injection. 
Visual stimulation protocol 
To trigger a neuronal response in the mouse brain, we exposed 
the eyes of head-fixed, lightly anesthetized darkness-habituated 
mice to a light stimulation protocol (Fig. 2A). The protocol 
comprised 3 sets of 15 seconds-long blue light flashes (470 nm 
LED, 3-6 Hz flashing frequency) interleaved with 45 seconds-
long periods of darkness (Fig. 2C). This protocol was designed 
to evoke responses in brain structures that are part of the visual 
system, namely the visual cortex, the superior colliculus and 
the lateral geniculate nucleus (LGN) (28). We selected our 
imaging plane to optimally capture the LGN and assess the 
subcortical imaging capabilities of enhanced fUS. For each 
experiment, we first conducted a baseline acquisition without 
any bolus administration, followed by a second acquisition 
during which we injected a bolus of either saline, GVs or MBs 
after a 45-second baseline period. We acquired 4 to 5 datasets 
for each group (saline, MBs and GVs), each in a separate 
mouse experiment. 
In vivo data processing 
After processing power Doppler images (Fig. 2B), we analyzed 
the signals recorded 90 seconds after the start of the 
acquisition, after the initial bolus peak has passed, leaving a 
relatively stable contrast (Fig. 2D). The Doppler data was 
denoised in the time domain using a 4-point moving average. 
To remove the slope of the post-bolus washout, we fitted the 
Doppler intensity time traces in every pixel with a linear 
regression model and subtracted the linear trend from the 
experimental data (Fig. 2E).  
 Neural activity maps (Fig. 2F) were generated by cross-
correlation of the temporal signal in each pixel of the de-
trended power Doppler datasets with the hemodynamic 
response function (HRF) to the stimulus. The HRF was 
computed based on a typical averaged response over all the 
voxels showing a response to light with a signal > 3 spatial 
standard deviations (STDs). 
 
Figure 2. Visual stimulation protocol. A/ Illustration of a lightly anesthetized, head fixed wild type mouse exposed to a flashing blue light. 
Probe positioned to capture the lateral geniculate nuclei (LGN). B/ Transcranial ultrafast Doppler image acquired at 2 Hz over the course of 
320 seconds. C/ Visual stimulation pattern (blue) and corresponding fUS signal response in the LGN in the presence of GVs (black). D/ Mean 
brain enhancement with and without GVs. E/ Truncated fUS signals in the most responsive pixel with and without GV injection. The predicted 
hemodynamic response function (HRF) is overlaid on the experimental activation patterns. F/ fUS activation maps revealing activation of the 
LGN. 
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In order to characterize the fast-time temporal fluctuation 
of the contrast-enhanced Doppler signal during the bolus 
washout phase (Fig. 3), we fitted the Doppler signal from t=60 
s with a double exponential function, which we subtracted 
from the data in every pixel. Subsequently, we derived the 
standard deviation of signal using a Gaussian distribution fit, 
and computed the variance as the square of the standard 
deviation. 
We overlaid neural activation maps on top of power 
Doppler images of the cerebral vasculature (Fig. 4B, D, F) using 
a threshold of 3 STDs above the noise level (8). 
Finally, we computed integrated correlation scores (Fig. 
4G-I) by summing the correlation score of each pixel above 3 
STDs within the masked brain image. Statistical significance 
before and after bolus injection was characterized using a two-
tailed paired t-test. All ultrasound images displayed in the 
manuscript were linearly interpolated by halving intervals in 
the x and y directions.  
Cerebral blood flow velocity computation 
We segmented SVD-filtered beamformed IQ data into discrete 
frequency bands of 20 Hz, which corresponds to velocity bands 
of 1 mm/s, using 6th-order Butterworth bandpass filters (10-
30 Hz to 50-70 Hz with increments of 10 Hz; and 80-100 Hz 
to 460-480 Hz with increments of 20 Hz). This processing 
approach enabled the generation of a set of power Doppler 
images that map cerebral blood flow in discrete velocity ranges 
of 1 mm/s (centered on 1 - 4.5 mm/s with increments of 0.5 
mm/s, and 5.5 – 23.5 mm/s with increments of 1 mm/s) (29). 
We subsequently analyzed the distribution of cerebral blood 
flow velocities in the activated LGN pixels (Fig. 5), that were 
segmented from the activation maps using a correlation 
coefficient threshold of 0.6. Finally, we computed the Doppler 
intensity in each band between during rest and during light-
evoked stimulation of the LGN in the absence and presence of 
GVs.  
 
Figure 3. GV enhancement of ultrafast ultrasound Doppler signals. A/ Mean brain signal change over time with and without saline. 
B/ Power Doppler images at 60s with and without saline. C/ (Top) Variance of the fUS signal fluctuation per pixel in the presence of saline. 
(Bottom) Histogram of the variance observed in image pixels. D/ Mean brain signal change over time with and without MBs. E/ Power Doppler 
images at peak enhancement with and without MBs. F/ (Top) Variance of the fUS signal fluctuation per pixel in the presence of MBs. (Bottom) 
Histogram of the variance observed in image pixels. G/ Mean brain signal change over time with and without GVs. H/ Power Doppler images 
at peak enhancement with and without GVs. I/ (Top) Variance of the fUS signal fluctuation per pixel in the presence of GVs. (Bottom) 
Histogram of the variance observed in image pixels. Scale bars represent 1 mm. 
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RESULTS 
GVs enhance Doppler contrast across velocities  
In vitro results showed that, at a 2 mm/s flow velocity, GVs can 
sustain ultrasound peak positive pressures ranging from 135 
kPa to 507 kPa without showing any decrease in CFR (Fig. 
1D). Above 507 kPa, the CFR enhancement of Doppler signals 
attributed to GVs decreased continuously down to 846 kPa, 
indicating that most GVs were collapsed at this pressure. In 
contrast, MBs began to collapse above 254 kPa (Fig. 1D). Being 
able to withstand higher insonation pressures is beneficial 
because the intensity of signals backscattered from both the 
endogenous red blood cells and the contrast agents typically 
scales as pressure squared.  
Our in vitro experiments also revealed that GVs are more 
accurate reporters of flow velocity below 500 μm/s than MBs 
and DF alone. At 254 kPa (Fig.1E), fluid containing GVs 
measured the syringe pump flow velocity accurately down to 
50 μm/s, while DF itself reflected flow velocity accurately 
down to 200 μm/s, and MBs where only accurate above 500 
μm/s. This may be due to the dominance of Stokes drag over 
other forces such as buoyancy in the case of GV nanoparticles, 
while playing a less dominant role for the larger MBs and DF 
particles. At 592 kPa (Fig. 1F), a partially destructive pressure 
level for both MBs and GVs, DF particles and MBs were 
accurate reporters of flow velocities down to 100 μm/s, 
whereas GVs where accurate reporters down to 50 μm/s flow 
velocities. The higher MB accuracy at high pressure is likely 
due to the higher SNR and to the destruction of static bubbles 
in the channel.  
 
Figure 4. GV enhancement of transcranial fUS signals. A/ C/ E/ fUS signals in the most responsive LGN pixel with and without bolus 
injection of saline, MBs, and GVs, respectively. B/ D/ F/ Activation maps overlaid on power Doppler images of the mouse brain with and 
without bolus injection of saline, MBs, and GVs, respectively. G/ H/ I/ Integrated correlation scores (number of pixels times their correlation 
score) with and without bolus injection of saline, MBs, and GVs, respectively. The points connected by the red lines correspond to the examples 
reported in B, D and F. Scale bars represent 1 mm. 
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 These results establish the basic ability of GVs to enhance 
Doppler contrast across a wider range of velocities and 
withstand higher insonation pressures than MBs. 
GVs yield smooth Doppler enhancement in vivo 
To compare the in vivo performance of MBs and GVs in 
enhancing power Doppler and fUS signals, we used a setup 
combining contrast agent injection, transcranial fUS imaging 
and stimulation of the visual system in anesthetized mice (Fig. 
2). We started by evaluating the power Doppler signal 
enhancement conferred by a single bolus injection of saline, 
MBs or GVs in the absence of light stimulation (Fig. 3). Key 
performance parameters included the magnitude of signal 
enhancement and the temporal noise, which are expected to 
have opposite impacts on the ability of fUS to detect neural 
activity. As expected, control injections of saline did not modify 
the Doppler signal intensity over time compared to the 
reference acquisition (Fig. 3A). Consequently, transcranial 
power Doppler images at t = 60 s without and with saline (Fig. 
3B) looked similar. For a saline injection, the mean variance of 
the fast-time fluctuation of the saline-enhanced Doppler signal 
was 0.66% (Fig. 3C).  
The bolus injection of MBs (Fig. 3D) enhanced the 
Doppler signal significantly, peaking at 149% compared to the 
pre-injection baseline level at t = 58.5 s. Transcranial power 
Doppler images at t = 58.5 s without and with MBs (Fig. 3E) 
revealed a clear enhancement across the entire brain due to 
MBs. The variance of the signal was characterized in the 
washout phase using a double exponential fit (R2 = 0.97). 
Following MB injection, the mean variance was 4.45% (Fig. 
3F), one order of magnitude above the saline value. 
The bolus injection of GVs (Fig. 3G) enhanced the 
Doppler signal by 34% compared to the pre-injection baseline 
level at t = 57.5 s. Transcranial power Doppler images at t = 
57.5 s without and with GVs (Fig. 3H) revealed a clear 
enhancement throughout the brain. The variance of the signal 
was characterized in the washout phase using a double 
exponential fit (R2 = 0.97). For the GV injection, the mean 
variance was 0.79% (Fig. 3I) – on the same order of magnitude 
as the saline value, and 5.6 times smaller than for MBs. These 
results demonstrate the ability of GVs to provide a similar 
magnitude of pseudo-steady hemodynamic contrast 
enhancement as MBs, while producing substantially less signal 
fluctuation. 
GVs enhance transcranial fUS signals in mice 
Next, we evaluated the enhancement of visually evoked fUS 
signals in the LGN of anesthetized mice after a single bolus 
injection of saline, MBs or GVs. fUS contrast was clearly 
observed for both the reference measurement (blood contrast 
alone) and after saline injection (Fig. 4A, B). In the single-trial 
recording shown in Fig. 4A, the peak fUS signal activation in 
the masked brain was 30% and 22%, without and with saline, 
respectively. In functional activation maps (Fig. 4B), the 
highest LGN correlation scores were 0.66 and 0.65, without 
and with saline injection, respectively. We observed that saline 
did slightly decrease correlation scores in activation maps, 
especially in the visual cortex. This may be due to the local 
dilution of the red blood cell concentration in the dense 
capillary networks of the cortex. 
In the single-trial recording reported in Fig. 4C, the peak 
fUS signal activation of the reference acquisition was 27%, and 
28% with MBs injected. However, the MB-enhanced fUS 
signal showed substantially larger fluctuations than the 
reference signal. As a result, in correlation maps (Fig. 4D), the 
highest LGN correlation score dropped from a pre-injection 
value of 0.70 to only 0.37 after MB injection, indicating that 
the statistical power to detect fUS signals resulting from neural 
activity diminished due to the large MB-induced signal 
fluctuation. 
In contrast, GVs produced enhanced fUS responses and 
statistical correlation. In the single-trial recording reported in 
Fig. 4E, the peak fUS signal activation of the reference 
acquisition was 25%, going up to 60% after GV injection. In 
correlation maps (Fig. 4F), the highest LGN correlation score 
in the reference acquisition was 0.75, and increased to 0.84 
with GVs administered, indicating a clear enhancement of 
functional signals. 
Overall findings in groups of N≥4 mice indicated a 
statistically significant increase in the integrated correlation 
score of fUS-recorded LGN activations with GVs administered 
compared to red blood cells alone (p-value = 0.046) (Fig. 4I). 
In contrast, saline and MB injections appeared to degrade fUS-
recorded LGN activations compared to red blood cells contrast 
(p-value = 0.006 and 0.113) (Fig. 4G, H). 
 
Figure 5. Distribution of cerebral blood flow velocities in the LGN. A/ Linear Doppler intensities in bandpass filtered velocity bins of 
1mm/s at baseline (black) and during activation (red) in the absence of GVs. B/ Linear Doppler intensities in bandpass filtered velocity bins of 
1mm/s at baseline (black) and during activation (red) in the presence of GVs. 
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To further characterize the impact of GV administration 
on the information content of hemodynamic fUS signals, we 
analyzed contrast enhancement as a function of the observed  
blood flow velocities in activated patches of the LGN by 
segmenting Doppler images into velocity bands of 1 mm/s (29). 
Fig. 5 reports the blood flow velocity profiles in the LGN (in 
pixels with correlation scores above 0.6) for the data set shown 
in Fig. 4F. In the absence of GVs (Fig. 5A), the cerebral blood 
flow velocity profile during light-evoked LGN activation 
revealed an overall increase of the Doppler intensity across all 
the cerebral blood flow velocities sampled (1 mm/s to 24 
mm/s) compared to the cerebral blood flow velocity profile at 
rest. In addition, a noticeable increase in Doppler intensity was 
observed around 10 mm/s.  In the presence of GVs (Fig. 5B), 
Doppler intensities were increased, and the enhancement did 
not significantly bias the cerebral blood flow velocity profiles, 
which remained similar to Fig. 5A. This indicates that GVs 
enhance all classes of vessels contributing to the fUS signals.  
DISCUSSION 
Together, our results establish the potential of GVs to serve as 
hemodynamic enhancers for functional ultrasound imaging. 
Our in vitro flow phantom experiments confirmed the 
hypothesis that GVs can enhance ultrasound Doppler signals 
on the same order of magnitude in a pseudo-steady state as 
MBs, but sustain higher ultrasound pressures (507 kPa versus 
254 kPa) and more accurately report low flow velocities (down 
to 50 µm/s). The first difference is of importance for ultrasound 
imaging because higher pressure transmission leads to a higher 
dynamic range in Doppler images. The second finding is 
critical for future efforts to extend fUS imaging to include the 
capillary level of cerebral vasculature, a vascular compartment 
which is currently poorly sensed by this technique due to 
limited sensitivity below a few mm/s (2), whereas capillary 
flows extend below 1 mm/s (30). 
Our in vivo results demonstrate that GVs provide similar 
pseudo-steady enhancement of Doppler signals compared to 
MBs (despite a lower peak enhancement),  without introducing 
additional temporal fluctuation into the Doppler signal. This 
smooth enhancement leads to a more effective functional 
signal amplification using GVs than MBs. This finding is 
consistent with the fact that GV nanostructures are relatively 
numerous, monodisperse and well-embedded in blood flow. In 
contrast, commercial MBs are polydisperse micron-scale 
contrast agents that respond acoustically in a non-coherent 
way. 
To enable longitudinal studies using GVs as intravascular 
fUS enhancers, the circulation time of GVs will need to be 
extended, for example using surface modifications such as 
PEGylation (31). In addition, the ability to engineer GV 
properties at the genetic level may enable the optimization of 
GVs for Doppler contrast. Finally, future studies could 
investigate the use of engineered GVs that exhibit nonlinear 
scattering (21, 24, 32) to increase the specificity and resolution 
of GV-enhanced functional ultrasound imaging. 
CONCLUSION 
Taken together, our results demonstrate that GVs provide 
superior performance as enhancers of fUS compared to MBs 
due to GVs’ ability to withstand higher pressure, more 
faithfully report slower flow velocities, and not increase the 
temporal fluctuation of the measurement. Further engineering 
for enhanced circulation time and brighter contrast would 
make GVs a preferred enhancer for fUS imaging. 
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